Bispecific antibody · Immune activation, directed at CD32B (FCGR2B) (FCGR2B) and CD79B · developed by MacroGenics
MGD010 is a DART (Dual Affinity Re-Targeting) bispecific antibody-based molecule that binds CD32B and CD79B. It is administered as a single agent and is studied in healthy subjects.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02376036 | Phase 1 | Healthy Subjects | Completed | MGNX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy Subjects
Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.
See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGNX catalysts and pipeline →